Zobrazeno 1 - 10
of 41
pro vyhledávání: '"Carina Vingsbo Lundberg"'
Autor:
Xiaoliang Ba, Claire L. Raisen, Olivier Restif, Lina Maria Cavaco, Carina Vingsbo Lundberg, Jean Y. H. Lee, Benjamin P. Howden, Mette D. Bartels, Birgit Strommenger, Ewan M. Harrison, Anders Rhod Larsen, Mark A. Holmes, Jesper Larsen
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-12 (2023)
Abstract Global spread of multidrug-resistant, hospital-adapted Staphylococcus epidermidis lineages underscores the need for new therapeutic strategies. Here we show that many S. epidermidis isolates belonging to these lineages display cryptic suscep
Externí odkaz:
https://doaj.org/article/7783deb913b548bca9efc7e2f97139c1
Autor:
Katharina Rox, Rolf Jansen, Tadeja Lukežič, Marina Greweling-Pils, Jennifer Herrmann, Marcus Miethke, Stephan Hüttel, Fabienne Hennessen, Antoine Abou Fayad, Cornelia Holzhausen, Carina Vingsbo Lundberg, Joanne Teague, Enge Sudarman, Lisa Bülter, Thomas Hesterkamp, Marc Stadler, Mark Brönstrup, Rolf Müller
Publikováno v:
Microbiology Spectrum, Vol 12, Iss 1 (2024)
ABSTRACT The quest for novel anti-infectives against drug-resistant pathogens of the so-called ESKAPE panel is accompanied by intensive research aiming to find treatment options for the future. In this study, we evaluated the pharmacokinetics and pha
Externí odkaz:
https://doaj.org/article/820d30d4e9e141c286291b4710977660
Autor:
Rakel Arrazuria, Bernhard Kerscher, Karen E. Huber, Jennifer L. Hoover, Carina Vingsbo Lundberg, Jon Ulf Hansen, Sylvie Sordello, Stephane Renard, Vincent Aranzana-Climent, Diarmaid Hughes, Philip Gribbon, Lena E. Friberg, Isabelle Bekeredjian-Ding
Publikováno v:
Frontiers in Microbiology, Vol 13 (2022)
The rise in antimicrobial resistance (AMR), and increase in treatment-refractory AMR infections, generates an urgent need to accelerate the discovery and development of novel anti-infectives. Preclinical animal models play a crucial role in assessing
Externí odkaz:
https://doaj.org/article/4b5b6c8d81a04eadbeb5ed8b76a1c875
Autor:
Rakel Arrazuria, Bernhard Kerscher, Karen E. Huber, Jennifer L. Hoover, Carina Vingsbo Lundberg, Jon Ulf Hansen, Sylvie Sordello, Stephane Renard, Vincent Aranzana-Climent, Diarmaid Hughes, Philip Gribbon, Lena E. Friberg, Isabelle Bekeredjian-Ding
Publikováno v:
Frontiers in Microbiology, Vol 13 (2022)
Antimicrobial resistance has become one of the greatest threats to human health, and new antibacterial treatments are urgently needed. As a tool to develop novel therapies, animal models are essential to bridge the gap between preclinical and clinica
Externí odkaz:
https://doaj.org/article/cee7cdc3abe644f0b3323bf66538e83e
Autor:
Anne Weiss, Emilie Delavenne, Carina Matias, Heimo Lagler, Daniel Simon, Ping Li, Jon U. Hansen, Teresa Pires dosSantos, Bimal Jana, Petra Priemel, Christine Bangert, Martin Bauer, Sabine Eberl, Alina Nussbaumer‐Pröll, Zoe Anne Österreicher, Peter Matzneller, Tamara Quint, Maria Weber, Hanne Mørck Nielsen, Thomas Rades, Helle Krogh Johansen, Henrik Westh, Wooseong Kim, Eleftherios Mylonakis, Christian Friis, Luca Guardabassi, John Pace, Carina Vingsbo Lundberg, Fatima M'Zali, Pascal Butty, Nikolaj Sørensen, Henrik Bjørn Nielsen, Rasmus Toft‐Kehler, Emma Guttman‐Yassky, Georg Stingl, Markus Zeitlinger, Morten Sommer
Publikováno v:
Clinical and Translational Medicine, Vol 12, Iss 5, Pp n/a-n/a (2022)
Abstract Background In patients with atopic dermatitis (AD), Staphylococcus aureus frequently colonizes lesions and is hypothesized to be linked to disease severity and progression. Treatments that reduce S. aureus colonization without significantly
Externí odkaz:
https://doaj.org/article/c12af968bd3a4c4badc928f617fc3d24
Autor:
Alysha G. Elliott, Johnny X. Huang, Søren Neve, Johannes Zuegg, Ingrid A. Edwards, Amy K. Cain, Christine J. Boinett, Lars Barquist, Carina Vingsbo Lundberg, Jason Steen, Mark S. Butler, Mehdi Mobli, Kaela M. Porter, Mark A. T. Blaskovich, Sergio Lociuro, Magnus Strandh, Matthew A. Cooper
Publikováno v:
Nature Communications, Vol 11, Iss 1, Pp 1-13 (2020)
Peptide antibiotics often display a very narrow therapeutic index. Here, the authors present an optimized peptide antibiotic with broad-spectrum in vitro activities, in vivo efficacy in multiple disease models against multidrug-resistant Gram-negativ
Externí odkaz:
https://doaj.org/article/c52da634b87d440cbbc0c10a3c254c56
Autor:
Katja Becker, Sha Cao, Anna Nilsson, Maria Erlandsson, Sven-Kevin Hotop, Janis Kuka, Jon Hansen, Klara Haldimann, Solveiga Grinberga, Talia Berruga-Fernández, Douglas L. Huseby, Reza Shariatgorji, Evelina Lindmark, Björn Platzack, Erik C. Böttger, David Crich, Lena E. Friberg, Carina Vingsbo Lundberg, Diarmaid Hughes, Mark Brönstrup, Per E. Andrén, Edgars Liepinsh, Sven N. Hobbie
Publikováno v:
EBioMedicine, Vol 73, Iss , Pp 103652- (2021)
Background: The clinical-stage drug candidate EBL-1003 (apramycin) represents a distinct new subclass of aminoglycoside antibiotics for the treatment of drug-resistant infections. It has demonstrated best-in-class coverage of resistant isolates, and
Externí odkaz:
https://doaj.org/article/b25c8a267d4642389bf6d5a2908a5a98
Autor:
Truc Hoang, Claus Aagaard, Jes Dietrich, Joseph P Cassidy, Gregory Dolganov, Gary K Schoolnik, Carina Vingsbo Lundberg, Else Marie Agger, Peter Andersen
Publikováno v:
PLoS ONE, Vol 8, Iss 12, p e80579 (2013)
The ESX systems from Mycobacterium tuberculosis are responsible for the secretion of highly immunogenic proteins of key importance for bacterial survival and growth. The two prototypic proteins, ESAT-6 (EsxA from ESX-1) and TB10.4 (EsxH from ESX-3) s
Externí odkaz:
https://doaj.org/article/91ae68379d044710b9fe964356157327
Autor:
Vincent Aranzana-Climent, Diarmaid Hughes, Sha Cao, Magdalena Tomczak, Malgorzata Urbas, Dorota Zabicka, Carina Vingsbo Lundberg, Jon Hansen, Johan Lindberg, Sven N. Hobbie, Lena E. Friberg
Publikováno v:
Clinical Microbiology and Infection. 28:1367-1374
Objectives: New drugs and methods to efficiently fight carbapenem-resistant gram-negative pathogens are sorely needed. In this study, we characterized the preclinical pharmacokinetics (PK) and pharmacodynamics of the clinical stage drug candidate apr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7a2582df4c2b82a4b309a3d25a8fc716
https://doi.org/10.1016/j.cmi.2022.05.003
https://doi.org/10.1016/j.cmi.2022.05.003
Autor:
Christine V.F. Carrington, Steven M Chamow, Adam S. Adler, Matthew Adams, Sheila M. Keating, Emma Pearce, Ashley Gras, Robert C. Edgar, Charles Olson, Dirk Büscher, Jasmeen Saini, Kyle P Carter, Ariel R Niedecken, Heather E. Lynch, Rachel Mosher, Ellen K. Wagner, Vishal A. Manickam, Renee Leong, Bishal K. Gautam, Jan Fredrik Simons, Marcus O. Muench, Matthew J. Spindler, Jose Vicente Terencio, LaRee Tracy, Brendan Tinsley, Thomas H. Oguin, David S. Johnson, Yao Chiang, Nicholas Wayham, Everett Meyer, Rena A. Mizrahi, Anushka T. Ramjag, Carl A. Ross, Carina Vingsbo Lundberg, David Goldblatt, Matthew J Walch, Yoong Wearn Lim, Jackson Leong, Michael A. Asensio, Lucy Roalfe, Robert Jeanfreau, Emily Benzie, Christopher R. Bartley, Graham Simmons, Hayley Richardson, Bryan Monroe, Angélica V Medina-Cucurella, Kacy Stadtmiller
Publikováno v:
Nature biotechnology
Plasma-derived polyclonal antibody therapeutics, such as intravenous immunoglobulin, have multiple drawbacks, including low potency, impurities, insufficient supply, and batch-to-batch variation. Here we describe a microfluidics and molecular genomic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ee8917bb26c73ba55ef1640d50a52b47
http://europepmc.org/articles/PMC8355030
http://europepmc.org/articles/PMC8355030